Zoonotic Infections News

Enrollment has begun for a phase 1 clinical trial of a recombinant nanoparticle vaccine for the treatment of Ebola virus, according to a press release from the vaccine’s manufacturer.

Using the common allergy antihistamine desloratadine may block the manganese transporter in Borrelia burgdorferi, the cause of Lyme disease, according to study results.

The Chikungunya virus can present symptoms similar to those of rheumatoid arthritis, and physicians evaluating suspected new rheumatoid arthritis in patients should ask patients about their travel history, according to newly published research.

Using a model constructed of epidemiological estimates for Ebola virus in Liberia, researchers have found that convalescent transfusion therapy could reduce mortality among patients hospitalized with the virus.

Researchers from Johns Hopkins University reported that the long-term consequences of Lyme disease infection is having a significant impact on the United States health care system — costing upwards of $1.3 billion annually, or almost $3,000 a patient on average.

Of the $2.89 billion of international aid pledged by donors, only $1.09 billion was received by Ebola-affected countries by Dec. 31, 2014, according to recently published data.

The results of a phase 1 clinical trial suggest a monovalent Ebola vaccine was safe and immunogenic in healthy adults, according to recently published data.

The chikungunya virus became known worldwide following an epidemic that originated in Kenya during 2004. More recently, the Caribbean and Central and South America saw a staggering number of cases during the 2014 outbreak.

Researchers have identified a genomic drift in the Ebola virus that may interfere with experimental treatments that were designed based on genetic sequences derived from earlier outbreaks, recent data in mBio suggest.

Seasonal deployment of various malaria interventions could reduce spread and reproduction of the disease, according to recently published data.